Acetyl Hexapeptide-8 (Leuphasyl)

Research-Grade

Acetyl Hexapeptide-8, commercially known as Leuphasyl, is a synthetic hexapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg that targets the neuromuscular junction through a mechanism distinct from but complementary to SNARE-targeting peptides like Argireline (acetyl hexapeptide-3). While Argireline inhibits SNARE complex formation (the exocytosis machinery), Leuphasyl acts upstream by mimicking enkephalin at the mu-opioid receptor on the presynaptic terminal, reducing the frequency and amplitude of nerve impulses that trigger muscle contraction. This dual-level approach — reducing both the nerve signal and the vesicle fusion machinery — has been proposed as a more effective strategy for topical muscle relaxation than targeting either mechanism alone. The peptide was developed based on the observation that enkephalins (endogenous opioid pentapeptides) naturally modulate neuromuscular transmission by reducing presynaptic calcium influx, which decreases the probability of acetylcholine vesicle release per nerve impulse. Leuphasyl mimics this modulatory effect with a synthetic sequence optimized for topical skin penetration and stability. The acetyl group at the N-terminus protects against aminopeptidase degradation, and the charged residues (Glu, Arg) were selected to enable receptor interaction while maintaining adequate skin permeability in appropriate formulation vehicles. In cosmeceutical studies, Leuphasyl has demonstrated wrinkle reduction of approximately 11-15% when used alone over 4 weeks, and up to 25% when combined with Argireline — a synergy attributed to the complementary targeting of upstream (nerve impulse frequency) and downstream (vesicle fusion) components of neuromuscular transmission. This combination approach has been adopted by several premium anti-aging skincare brands. The peptide is classified as a cosmetic ingredient and has no drug regulatory status in any jurisdiction. Safety data from topical application studies shows no significant adverse effects at cosmeceutical concentrations.